All Stories

  1. Deficiency of ZC3HC1 Modulates Vascular Smooth Muscle Cell Phenotype and Increases Neointima Formation
  2. Clinical Proteomics in Cardiovascular Medicine: Current Capabilities, Limitations, and Future Directions
  3. Anti‐Malondialdehyde Low‐Density Lipoprotein Antibodies and Valvular Calcification: A Substudy of the SCOT‐HEART Trial
  4. A genetic map of human metabolism across the allele frequency spectrum
  5. Precision medicine requires precision proteomics: Discordance between proteomic and clinical assays in UK Biobank
  6. Cardiac regeneration beyond stem cells: harnessing sarcomere dynamics and endogenous repair mechanisms
  7. Platelets and inflammation—insights from platelet non-coding RNA content and release in the Bruneck study and the PACMAN-AMI trial
  8. ECM Modifications Driven by Age and Metabolic Stress Directly Promote Vascular Smooth Muscle Cell Osteogenic Processes
  9. Transcriptional Atlas of Cardiac Disease
  10. A genetic map of human metabolism across the allele frequency spectrum
  11. Cervical Artery Tortuosity Is Associated With Dissection Occurrence and Late Recurrence: A Nested Case-Control Study
  12. Dissecting the effect of genetic variants on atherosclerosis: integrating bulk and single-cell transcriptomics
  13. Differential effects of physiological agonists on the proteome of platelet‐derived extracellular vesicles
  14. Longitudinal Lipidomic Signature of Coronary Heart Disease in American Indian People
  15. Enhancing cardiovascular risk prediction through proteomics?
  16. Inhibition of miR-199a-3p in a murine hypertrophic cardiomyopathy (HCM) model attenuates fibrotic remodeling
  17. Phenylalanine-tRNA aminoacylation is compromised by ALS/FTD-associated C9orf72 C4G2 repeat RNA
  18. Proteomic Atlas of Atherosclerosis: The Contribution of Proteoglycans to Sex Differences, Plaque Phenotypes, and Outcomes
  19. Human blood vessel organoids reveal a critical role for CTGF in maintaining microvascular integrity
  20. Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial
  21. SERCA2a Protein Levels Are Unaltered in Human Heart Failure
  22. Cross-Linking Mass Spectrometry Uncovers Interactions Between High-Density Lipoproteins and the SARS-CoV-2 Spike Glycoprotein
  23. Uncovering Protein Networks in Cardiovascular Proteomics
  24. Reducing reductionism: addressing risk for atherosclerotic cardiovascular disease by apolipoprotein proteomics
  25. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction
  26. Desmosomal protein degradation as an underlying cause of arrhythmogenic cardiomyopathy
  27. Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease
  28. CNP Promotes Antiarrhythmic Effects via Phosphodiesterase 2
  29. Letter by Gutmann et al Regarding Article, “Circulating MicroRNA-122-5p Is Associated With a Lack of Improvement in Left Ventricular Function After Transcatheter Aortic Valve Replacement and Regulates Viability of Cardiomyocytes Through Extracellular V...
  30. Extracellular Matrix Profiling and Disease Modelling in Engineered Vascular Smooth Muscle Cell Tissues
  31. Temporal in vivo platelet labeling in mice reveals age-dependent receptor expression and conservation of specific mRNAs
  32. Reduced secretion of neuronal growth regulator 1 contributes to impaired adipose-neuronal crosstalk in obesity
  33. Vascular smooth muscle cell senescence accelerates medin aggregation via small extracellular vesicle secretion and extracellular matrix reorganization
  34. SGLT2 inhibitors in heart failure: insights from plasma proteomics
  35. Phenylalanine-tRNA aminoacylation is compromised by ALS/FTD-associated C9orf72 C4G2 repeat RNA
  36. Integrative single-cell meta-analysis reveals disease-relevant vascular cell states and markers in human atherosclerosis
  37. SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
  38. Human blood vessel organoids reveal a critical role for CTGF in maintaining microvascular integrity
  39. Serial measurements of protein and microRNA biomarkers to specify myocardial infarction subtypes
  40. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction
  41. Precision Medicine Approach for Cardiometabolic Risk Factors in Therapeutic Apheresis
  42. Correction: Precision Medicine Approach for Cardiometabolic Risk Factors in Therapeutic Apheresis
  43. Methods for the identification and characterization of extracellular vesicles in cardiovascular studies: from exosomes to microvesicles
  44. Circulating microRNAs as biomarkers and mediators of platelet activation
  45. Sexual dimorphism in COVID-19: potential clinical and public health implications
  46. Linking Genetics and Proteomics: Gene-Protein Associations Built on Diversity
  47. Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart
  48. Association of adolescent lipoprotein subclass profile with carotid intima-media thickness and comparison to adults: Prospective population-based cohort studies
  49. Isolation of Circulating Extracellular Vesicles by High-Performance Size-Exclusion Chromatography
  50. Neutrophil-Derived Protein S100A8/A9 Alters the Platelet Proteome in Acute Myocardial Infarction and Is Associated With Changes in Platelet Reactivity
  51. Extracellular Matrix in Heart Failure: Role of ADAMTS5 in Proteoglycan Remodeling
  52. Temporal in vivo platelet labelling in mice reveals age-dependent receptor expression and conservation of specific mRNAs
  53. Proteome and functional decline as platelets age in the circulation
  54. PCSK9 Activity Is Potentiated Through HDL Binding
  55. Association of cardiometabolic microRNAs with COVID-19 severity and mortality
  56. Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)–Related Cardiomyopathy: Development of PLN-R14del–Related Cardiomyopathy
  57. Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation
  58. Endothelial cells exposed to atheroprotective flow secrete follistatin-like 1 protein which reduces transcytosis and inflammation
  59. DRP1: a novel regulator of PCSK9 secretion and degradation
  60. Lessons from the spatiotemporal expression patterns of RNA vs. proteins during the cell cycle
  61. SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care
  62. Proteome and functional decline as platelets age in the circulation
  63. Lipoprotein compartmentalisation as a regulator of PCSK9 activity
  64. The Landscape of Coding and Noncoding RNAs in Platelets
  65. Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation
  66. Fibroblast GATA-4 and GATA-6 promote myocardial adaptation to pressure overload by enhancing cardiac angiogenesis
  67. The transCampus Metabolic Training Programme Explores the Link of SARS-CoV-2 Virus to Metabolic Disease
  68. Fibroblast Nox2 (NADPH Oxidase-2) Regulates ANG II (Angiotensin II)–Induced Vascular Remodeling and Hypertension via Paracrine Signaling to Vascular Smooth Muscle Cells
  69. Loss of hepatic miR-33 improves metabolic homeostasis and liver function without altering body weight or atherosclerosis
  70. A Proteomics-Based Assessment of Inflammation Signatures in Endotoxemia
  71. Systems biology in cardiovascular disease: a multiomics approach
  72. SARS-CoV-2 RNAemia and proteomic biomarker trajectory inform prognostication in COVID-19 patients admitted to intensive care
  73. Proteomic landscape of TGF-β1-induced fibrogenesis in renal fibroblasts
  74. Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia
  75. Metabolic recovery after weight loss surgery is reflected in serum microRNAs
  76. Extracellular matrix protein signature of recurrent spontaneous cervical artery dissection
  77. Cathepsin A contributes to left ventricular remodeling by degrading extracellular superoxide dismutase in mice
  78. Right Ventricle Has Normal Myofilament Function But Shows Perturbations in the Expression of Extracellular Matrix Genes in Patients With Tetralogy of Fallot Undergoing Pulmonary Valve Replacement
  79. Platelet “-omics” in health and cardiovascular disease
  80. Very preterm birth results in later lower platelet activation markers
  81. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart
  82. Platelet Reactivity in Individuals Over 65 Years Old Is Not Modulated by Age
  83. Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease
  84. microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring
  85. Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function
  86. Extracellular Matrix in Vascular Disease, Part 2/4
  87. Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition
  88. Pkm2 Regulates Cardiomyocyte Cell Cycle and Promotes Cardiac Regeneration
  89. The ‘Digital Twin’ to enable the vision of precision cardiology
  90. Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure
  91. High-Density Lipoproteins Are the Main Carriers of PCSK9 in the Circulation
  92. FURIN Expression in Vascular Endothelial Cells Is Modulated by a Coronary Artery Disease–Associated Genetic Variant and Influences Monocyte Transendothelial Migration
  93. ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis
  94. Preclinical development of a miR-132 inhibitor for heart failure treatment
  95. Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels
  96. Cartilage-like composition of keloid scar extracellular matrix suggests fibroblast mis-differentiation in disease
  97. Glycoproteomic Analysis of the Aortic Extracellular Matrix in Marfan Patients
  98. TIP 30 counteracts cardiac hypertrophy and failure by inhibiting translational elongation
  99. A Plasma Proteogenomic Signature for Fibromuscular Dysplasia
  100. Response by Schulte et al to Letter Regarding Article, “Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury”
  101. Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury
  102. Apolipoprotein Profiles in Very Preterm and Term‐Born Preschool Children
  103. Optogenetic Monitoring of the Glutathione Redox State in Engineered Human Myocardium
  104. Locally different proteome in aortas from patients with stenotic tricuspid and bicuspid aortic valves†
  105. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology
  106. MicroRNAs: A New Understanding of Platelet Physiology and Pathology
  107. The Emerging Role of the ADAMTS Family in Vascular Diseases
  108. In Aptamers They Trust
  109. Inhibition of profibrotic microRNA-21 affects platelets and their releasate
  110. Hypoxia-induced epigenetic silencing of polo-like kinase 2 promotes fibrosis in atrial fibrillation
  111. Characterisation of circulating biomarkers before and after cardiac resynchronisation therapy and their role in predicting CRT response: the COVERT-HF study
  112. Higher spermidine intake is linked to lower mortality: a prospective population-based study
  113. Role of ADAMTS-5 in Aortic Dilatation and Extracellular Matrix Remodeling
  114. Extracellular Vesicle Crosstalk Between the Myocardium and Immune System Upon Infarction
  115. Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology
  116. Expanding the horizons of microRNA bioinformatics
  117. MicroRNA-24 and the Diabetic Heart
  118. Non-coding RNAs in vascular disease – from basic science to clinical applications: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology
  119. MicroRNA-21 and the Vulnerability of Atherosclerotic Plaques
  120. Downregulation of MicroRNA-126 Augments DNA Damage Response in Cigarette Smokers and Patients with Chronic Obstructive Pulmonary Disease
  121. Correction: Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease
  122. Cardiovascular Risk Beyond Low-Density Lipoprotein Cholesterol
  123. The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC
  124. Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries
  125. Nox4 reprograms cardiac substrate metabolism via protein O-GlcNAcylation to enhance stress adaptation
  126. Comparison of MOLLI, shMOLLLI, and SASHA in discrimination between health and disease and relationship with histologically derived collagen volume fraction
  127. Plasma Proteomics for Epidemiology
  128. Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling
  129. An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology
  130. Genetic Dissection of the Impact of miR-33a and miR-33b during the Progression of Atherosclerosis
  131. Very low-density lipoprotein associated apolipoproteins predict cardiovascular events and are lowered by inhibition of apoC-III
  132. CRISPR/Cas9 editing reveals novel mechanisms of clustered microRNA regulation and function
  133. What are the prospects of apolipoprotein profiling for cardiovascular disease?
  134. Cardiac myocyte β3-adrenergic receptors prevent myocardial fibrosis by modulating oxidant stress-dependent paracrine signaling
  135. Long Noncoding RNAs and Angiogenesis
  136. Proteomics of the epicardial fat secretome and its role in post-operative atrial fibrillation
  137. 195 Crispr/cas9 gene editing reveals novel tertiary constraints in clustered mirna processing
  138. Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease
  139. Association Between Vascular Cell Adhesion Molecule 1 and Atrial Fibrillation
  140. Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart
  141. Mitochondria and ageing: role in heart, skeletal muscle and adipose tissue
  142. Glycoproteomics of the Extracellular Matrix: A Method for Intact Glycopeptide Analysis Using Mass Spectrometry
  143. Reply
  144. Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques
  145. High-density lipoproteins in high resolution: Will proteomics solve the paradox for cardiovascular risk?
  146. Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III
  147. MicroRNA Biomarkers and Platelet Reactivity
  148. Premature senescence of endothelial cells upon chronic exposure to TNFα can be prevented by N-acetyl cysteine and plumericin
  149. Diabetes Mellitus–Induced Microvascular Destabilization in the Myocardium
  150. MicroRNAs in Cardiovascular Disease
  151. Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes
  152. Potential and Caveats of Lipidomics for Cardiovascular Disease
  153. Cardioprotection and lifespan extension by the natural polyamine spermidine
  154. Native T1 and T2 mapping by CMR in lupus myocarditis: Disease recognition and response to treatment
  155. From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on “New frontiers in cardiovascular research”
  156. Systems biology—opportunities and challenges: the application of proteomics to study the cardiovascular extracellular matrix
  157. Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation
  158. Caveats of Untargeted Metabolomics for Biomarker Discovery ∗
  159. Identification of cyclins A1, E1 and vimentin as downstream targets of heme oxygenase-1 in vascular endothelial growth factor-mediated angiogenesis
  160. Proteomic and metabolomic changes driven by elevating myocardial creatine suggest novel metabolic feedback mechanisms
  161. Chronic miR‐29 antagonism promotes favorable plaque remodeling in atherosclerotic mice
  162. Loss of Biglycan Enhances Thrombin Generation in Apolipoprotein E -Deficient Mice
  163. Oxidant-induced Interprotein Disulfide Formation in Cardiac Protein DJ-1 Occurs via an Interaction with Peroxiredoxin 2
  164. Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?
  165. Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veins
  166. Pharmacogenetics of Clopidogrel
  167. Vascular proteomics in metabolic and cardiovascular diseases
  168. “Young at heart”: Regenerative potential linked to immature cardiac phenotypes
  169. Guidelines for the functional annotation of microRNAs using the Gene Ontology
  170. Association of MicroRNAs and YRNAs With Platelet Function
  171. When Sweet Turns Salty
  172. Correlates of serum hepcidin levels and its association with cardiovascular disease in an elderly general population
  173. Meeting report from the 2nd International Symposium on New Frontiers in Cardiovascular Research. Protecting the cardiovascular system from ischemia: between bench and bedside
  174. Comparative analysis of statistical methods used for detecting differential expression in label-free mass spectrometry proteomics
  175. Inadequate hepcidin serum concentrations predict incident type 2 diabetes mellitus
  176. MicroRNA Biomarkers for Coronary Artery Disease?
  177. XBP 1-Deficiency Abrogates Neointimal Lesion of Injured Vessels Via Cross Talk With the PDGF Signaling
  178. Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes
  179. Transformative Impact of Proteomics on Cardiovascular Health and Disease
  180. Sweet Dicer
  181. The cardiovascular gene annotation initiative: Impact on data analysis
  182. Asymmetric Dimethylarginine and Cardiovascular Risk: Systematic Review and Meta‐Analysis of 22 Prospective Studies
  183. Novel methodologies for biomarker discovery in atherosclerosis
  184. Proteomic analyses reveal that loss of TDP-43 affects RNA processing and intracellular transport
  185. Vascular Smooth Muscle Cell Calcification Is Mediated by Regulated Exosome Secretion
  186. ADAMTS-7 Inhibits Re-endothelialization of Injured Arteries and Promotes Vascular Remodeling Through Cleavage of Thrombospondin-1
  187. T1 values by conservative septal postprocessing approach are superior in relating to the interstitial myocardial fibrosis: findings from patients with severe aortic stenosis
  188. Cardiac-targeted NADPH oxidase 4 in the adaptive cardiac remodelling of the murine heart
  189. Affinity Proteomics for Phosphatase Interactions in Atrial Fibrillation∗
  190. Native T1 in Discrimination of Acute and Convalescent Stages in Patients With Clinical Diagnosis of Myocarditis
  191. Lipidomics
  192. Role of miR-195 in Aortic Aneurysmal Disease
  193. “Going Long”: Long Non-Coding RNAs as Biomarkers
  194. Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)
  195. Long‐term therapeutic silencing of miR‐33 increases circulating triglyceride levels and hepatic lipid accumulation in mice
  196. Redox State of Pentraxin 3 as a Novel Biomarker for Resolution of Inflammation and Survival in Sepsis
  197. Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study
  198. Cardiac fibroblast–derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy
  199. Tracing the Proteomic Fingerprint of the Diabetic Aorta?
  200. Targeting myocardial remodelling to develop novel therapies for heart failure
  201. Effects of Heparin on Temporal MicroRNA Profiles
  202. ESC Working Group on Myocardial Function Position Paper: how to study the right ventricle in experimental models
  203. Signature of circulating microRNAs in osteoarthritis
  204. LDL-receptor-deficient mice lacking microRNA-143/145 have less atherosclerosis
  205. Matrix Metalloproteinase-8 Promotes Vascular Smooth Muscle Cell Proliferation and Neointima Formation
  206. Phosphoregulation of the Titin-cap Protein Telethonin in Cardiac Myocytes
  207. Gene Network and Proteomic Analyses of Cardiac Responses to Pathological and Physiological Stress
  208. Impaired Antioxidant Defenses and Redox Signaling in GDM Fetal Endothelial Cells
  209. Histone Deacetylase 3 Unconventional Splicing Mediates Endothelial-to-mesenchymal Transition through Transforming Growth Factor β2
  210. Extracellular Matrix Secretion by Cardiac Fibroblasts
  211. Multidimensional separation prior to mass spectrometry: Getting closer to the bottom of the iceberg
  212. Oxidative stress in atherosclerosis: The role of microRNAs in arterial remodeling
  213. The Hypoxia-Inducible MicroRNA Cluster miR-199a∼214 Targets Myocardial PPARδ and Impairs Mitochondrial Fatty Acid Oxidation
  214. Macrophage MicroRNA-155 Promotes Cardiac Hypertrophy and Failure
  215. Heterogeneity in Neutrophil Microparticles Reveals Distinct Proteome and Functional Properties
  216. Proteomics and Metabolomics for Mechanistic Insights and Biomarker Discovery in Cardiovascular Disease
  217. Vascular Proteomics - The Forgotten Blood Vessels
  218. La proteómica y la metabolómica: los mecanismos de la enfermedad cardiovascular y el descubrimiento de biomarcadores
  219. MicroRNA biomarkers for failing hearts?
  220. Proteomics in aortic aneurysm - What have we learnt so far?
  221. Endothelial Seeding for Abdominal Aortic Aneurysms
  222. Glycoproteomic Analysis of the Secretome of Human Endothelial Cells
  223. Native T1 Mapping in Differentiation of Normal Myocardium From Diffuse Disease in Hypertrophic and Dilated Cardiomyopathy
  224. Circulating MicroRNAs as Novel Biomarkers for Platelet Activation
  225. From data gathering to systems medicine
  226. Effects of perhexiline-induced fuel switch on the cardiac proteome and metabolome
  227. MicroRNAs Within the Continuum of Postgenomics Biomarker Discovery
  228. Proteomic Identification of Matrix Metalloproteinase Substrates in the Human Vasculature
  229. Functional Role of Matrix Metalloproteinase-8 in Stem/Progenitor Cell Migration and Their Recruitment Into Atherosclerotic Lesions
  230. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease
  231. A Sequential Extraction Methodology for Cardiac Extracellular Matrix Prior to Proteomics Analysis
  232. Cytochrome P4502S1: a novel monocyte/macrophage fatty acid epoxygenase in human atherosclerotic plaques
  233. Proteomics: from single molecules to biological pathways
  234. Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events
  235. Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes
  236. Prospective Study on Circulating MicroRNAs and Risk of Myocardial Infarction
  237. Novel Role of ADAMTS-5 Protein in Proteoglycan Turnover and Lipoprotein Retention in Atherosclerosis
  238. European Perspectives
  239. The -omics era: Proteomics and lipidomics in vascular research
  240. Proteomics Analysis of Cardiac Extracellular Matrix Remodeling in a Porcine Model of Ischemia/Reperfusion Injury
  241. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs
  242. Review focus on the role of microRNA in cardiovascular biology and disease
  243. MicroRNAs in Vascular and Metabolic Disease
  244. Analytical challenges and technical limitations in assessing circulating MiRNAs
  245. Pathogenesis of Varicose Veins
  246. Method for Protein Subfractionation of Cardiovascular Tissues Before DIGE Analysis
  247. Proteomics of Atherosclerosis
  248. Terminal Differentiation, Advanced Organotypic Maturation, and Modeling of Hypertrophic Growth in Engineered Heart Tissue
  249. Profiling of circulating microRNAs: from single biomarkers to re-wired networks
  250. Chromobox Protein Homolog 3 Is Essential for Stem Cell Differentiation to Smooth Muscles In Vitro and in Embryonic Arteriogenesis
  251. Extracellular Matrix Composition and Remodeling in Human Abdominal Aortic Aneurysms: A Proteomics Approach
  252. Nitrosative protein oxidation is modulated during early endotoxemia
  253. Recent Highlights of Metabolomics in Cardiovascular Research
  254. Substrate Modifications Precede the Development of Atrial Fibrillation After Cardiac Surgery: A Proteomic Study
  255. Calcium Regulates Key Components of Vascular Smooth Muscle Cell–Derived Matrix Vesicles to Enhance Mineralization
  256. Comparative Lipidomics Profiling of Human Atherosclerotic Plaques
  257. From Bench to Bedside: What Physicians Need to Know About Endothelial Progenitor Cells
  258. Metabolic homeostasis is maintained in myocardial hibernation by adaptive changes in the transcriptome and proteome
  259. Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas
  260. Proteomics
  261. Redox Regulation of Soluble Epoxide Hydrolase by 15-Deoxy-Δ-Prostaglandin J 2 Controls Coronary Hypoxic Vasodilation
  262. Cardiovascular stem cells revisited
  263. Proteomic characterization of human early pro-angiogenic cells
  264. Does Late Enhancement Imaging Decipher the Role of Myocardial Fibrosis in Hypertrophic Cardiomyopathy?
  265. Preoperative high-dose atorvastatin for prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial
  266. Highlights from the 2010 BAS/BSCR spring meeting: New Frontiers in Cardiovascular Research
  267. Plasma MicroRNA Profiling Reveals Loss of Endothelial MiR-126 and Other MicroRNAs in Type 2 Diabetes
  268. Human cardiac and bone marrow stromal cells exhibit distinctive properties related to their origin
  269. Proteomics Characterization of Extracellular Space Components in the Human Aorta
  270. Short Communication: Asymmetric Dimethylarginine Impairs Angiogenic Progenitor Cell Function in Patients With Coronary Artery Disease Through a MicroRNA-21–Dependent Mechanism
  271. Comparative Proteomics Profiling Reveals Role of Smooth Muscle Progenitors in Extracellular Matrix Production
  272. Coupling Vascular and Myocardial Inflammatory Injury into a Common Phenotype of Cardiovascular Dysfunction: Systemic Inflammation and Aging – A Mini-Review
  273. Histone Deacetylase 7 Controls Endothelial Cell Growth Through Modulation of β-Catenin
  274. Phenotyping transgenic animals—An integrated readout of pathophysiology by combining proteomics and metabolomics with cardiovascular imaging
  275. Proteomics Analysis of the Cardiac Myofilament Subproteome Reveals Dynamic Alterations in Phosphatase Subunit Distribution
  276. Proteomic analysis of the secretome of human umbilical vein endothelial cells using a combination of free-flow electrophoresis and nanoflow LC-MS/MS
  277. Identification of Cardiac Myosin-binding Protein C as a Candidate Biomarker of Myocardial Infarction by Proteomics Analysis
  278. Proteomics, Metabolomics, and Immunomics on Microparticles Derived From Human Atherosclerotic Plaques
  279. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures
  280. Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population
  281. Proteomics of acute coronary syndromes
  282. Proteomic and metabolomic analysis of cardioprotection: Interplay between protein kinase C epsilon and delta in regulating glucose metabolism of murine hearts
  283. Proteomics Identifies Thymidine Phosphorylase As a Key Regulator of the Angiogenic Potential of Colony-Forming Units and Endothelial Progenitor Cell Cultures
  284. Metabolomics
  285. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study
  286. Letter by Metzler et al Regarding Article, “Intracoronary KAI-9803 as an Adjunct to Primary Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction”
  287. Cardiovascular Proteomics
  288. Proteomic analysis of secretory proteins and vesicles in vascular research
  289. Proteomic and Metabolomic Analysis of Smooth Muscle Cells Derived From the Arterial Media and Adventitial Progenitors of Apolipoprotein E–Deficient Mice
  290. The Paradox of Hypoxic and Oxidative Stress in Atherosclerosis⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Car...
  291. Combined Metabolomic and Proteomic Analysis of Human Atrial Fibrillation
  292. Integrated Membrane Protein Analysis of Mature and Embryonic Stem Cell-derived Smooth Muscle Cells Using a Novel Combination of CyDye/Biotin Labeling
  293. Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes
  294. Protein Kinase D Selectively Targets Cardiac Troponin I and Regulates Myofilament Ca 2+ Sensitivity in Ventricular Myocytes
  295. Proteomics and Metabolomics Combined in Cardiovascular Research
  296. Proteomic analysis reveals higher demand for antioxidant protection in embryonic stem cell-derived smooth muscle cells
  297. The role of oxidant stress in angiotensin II-mediated contraction of human resistance arteries in the state of health and the presence of cardiovascular disease
  298. Proteomics-based Development of Biomarkers in Cardiovascular Disease
  299. Oxidized Low-Density Lipoprotein Autoantibodies, Chronic Infections, and Carotid Atherosclerosis in a Population-Based Study
  300. Oxidized Phospholipids Predict the Presence and Progression of Carotid and Femoral Atherosclerosis and Symptomatic Cardiovascular Disease
  301. Association of Serum-Soluble Heat Shock Protein 60 With Carotid Atherosclerosis
  302. Metabolic profiling of hypoxia-inducible factor-1β-deficient and wild type Hepa-1 cells: effects of hypoxia measured by 1H magnetic resonance spectroscopy
  303. Proteomic dataset of Sca-1+ progenitor cells
  304. Proteomic dataset of mouse aortic smooth muscle cells
  305. Proteomic and Metabolomic Analyses of Atherosclerotic Vessels From Apolipoprotein E-Deficient Mice Reveal Alterations in Inflammation, Oxidative Stress, and Energy Metabolism
  306. Role of oxidative stress in angiotensin-II mediated contraction of human conduit arteries in patients with cardiovascular disease
  307. Vascular proteomics: Linking proteomic and metabolomic changes
  308. Pitfalls of Proteomics
  309. Ischemic preconditioning exaggerates cardiac damage in PKC-δ null mice
  310. Loss of PKC-δ alters cardiac metabolism
  311. Proteomic and Metabolomic Analysis of Vascular Smooth Muscle Cells
  312. Cross-Reactive B-Cell Epitopes of Microbial and Human Heat Shock Protein 60/65 in Atherosclerosis
  313. Mechanical Stretch-Induced Apoptosis in Smooth Muscle Cells Is Mediated by β 1 -Integrin Signaling Pathways
  314. Increased Risk of Atherosclerosis Is Confined to CagA-Positive Helicobacter pylori Strains
  315. Both Donor and Recipient Origins of Smooth Muscle Cells in Vein Graft Atherosclerotic Lesions
  316. Smooth Muscle Cells in Transplant Atherosclerotic Lesions Are Originated From Recipients, but Not Bone Marrow Progenitor Cells
  317. Active and Passive Smoking, Chronic Infections, and the Risk of Carotid Atherosclerosis
  318. Mechanical Stress‐induced DNA damage and rac‐p38MAPK Signal Pathways Mediate p53‐dependent Apoptosis in Vascular Smooth Muscle Cells
  319. Loss of p53 Accelerates Neointimal Lesions of Vein Bypass Grafts in Mice
  320. Exacerbated vein graft arteriosclerosis in protein kinase Cδ–null mice
  321. Smooth muscle cell apoptosis in arteriosclerosis
  322. Chronic Infections and the Risk of Carotid Atherosclerosis
  323. Infections, Immunity, and Atherosclerosis
  324. Rapid Development of Vein Graft Atheroma in ApoE-Deficient Mice
  325. Serum Soluble Heat Shock Protein 60 Is Elevated in Subjects With Atherosclerosis in a General Population
  326. Reduced Neointima Hyperplasia of Vein Bypass Grafts in Intercellular Adhesion Molecule-1–Deficient Mice
  327. Association of Serum Antibodies to Heat-Shock Protein 65 With Carotid Atherosclerosis
  328. Cyclic Strain Stress-induced Mitogen-activated Protein Kinase (MAPK) Phosphatase 1 Expression in Vascular Smooth Muscle Cells Is Regulated by Ras/Rac-MAPK Pathways
  329. Inhibition of Arteriosclerosis by T-Cell Depletion in Normocholesterolemic Rabbits Immunized With Heat Shock Protein 65
  330. Endothelial Cytotoxicity Mediated by Serum Antibodies to Heat Shock Proteins of Escherichia coli and Chlamydia pneumoniae
  331. Macrophage-lysis mediated by autoantibodies to heat shock protein 65/60